These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

Tourism Holdings stalls as NZ sharemarket ends week on high
Markets Market Close

Tourism Holdings stalls as NZ sharemarket ends week on high

The NZ sharemarket bounced back as large-cap stocks balanced gains and losses.

Forsyth Barr shifts Turners Automotive to neutral
Markets

Forsyth Barr shifts Turners Automotive to neutral

The company has delivered five consecutive years of record earnings.

Vital board backs Tait takeover
Markets

Vital board backs Tait takeover

Vital’s board has unanimously recommended that shareholders and option holders accept a full takeover offer from Tait Communications, despite their view that it undervalues the company.In May, Vital shares rallied after it disclosed that Tait, a Christchurch-based critical commun...

Drury’s ASX stag, MetroGlass’s new owner, and more
Markets Small Cap Wrap

Drury’s ASX stag, MetroGlass’s new owner, and more

Rod Drury goes ‘pre-revenue’ again, plus small cap news from NZ.